A 0 1 0 1 O
New 2 5 2 5 B-clinical_variable
York 6 10 6 10 I-clinical_variable
Heart 11 16 11 16 I-clinical_variable
Association 17 28 17 28 I-clinical_variable
( 29 30 29 30 I-clinical_variable
NYHA 30 34 30 34 I-clinical_variable
) 34 35 34 35 I-clinical_variable
classification 36 50 36 50 I-clinical_variable
of 51 53 51 53 O
II 54 56 54 56 O
controlled 57 67 57 67 O
with 68 72 68 72 O
treatment 73 82 73 82 B-treatment

A 0 1 83 84 O
major 2 7 85 90 B-treatment
surgical 8 16 91 99 I-treatment
procedure 17 26 100 109 I-treatment
, 26 27 109 110 O
open 28 32 111 115 B-treatment
biopsy 33 39 116 122 I-treatment
, 39 40 122 123 O
or 41 43 124 126 O
significant 44 55 127 138 O
traumatic 56 65 139 148 O
injury 66 72 149 155 O
within 73 79 156 162 O
28 80 82 163 165 B-upper_bound
days 83 87 166 170 I-upper_bound
prior 88 93 171 176 I-upper_bound
to 94 96 177 179 O
starting 97 105 180 188 O
cediranib 106 115 189 198 B-treatment
( 116 117 199 200 O
percutaneous 117 129 200 212 B-treatment
/ 129 130 212 213 I-treatment
endobronchial 130 143 213 226 I-treatment
biopsies 144 152 227 235 I-treatment
are 153 156 236 239 O
allowed 157 164 240 247 O
) 164 165 247 248 O

A 0 1 249 250 O
urine 2 7 251 256 O
protein 8 15 257 264 B-clinical_variable
: 15 16 264 265 O
creatinine 17 27 266 276 B-clinical_variable
ratio 28 33 277 282 I-clinical_variable
of 34 36 283 285 O
< 37 38 286 287 O
1 39 40 288 289 B-upper_bound
or 41 43 290 292 O
< 44 45 293 294 O
1 46 47 295 296 B-upper_bound
g 48 49 297 298 I-upper_bound
protein 50 57 299 306 O
on 58 60 307 309 O
24 61 63 310 312 O
- 63 64 312 313 O
hour 64 68 313 317 O
urine 69 74 318 323 O
collection 75 85 324 334 O

Absolute 0 8 335 343 B-clinical_variable
neutrophil 9 19 344 354 I-clinical_variable
count 20 25 355 360 I-clinical_variable
> 26 27 361 362 O
= 27 28 362 363 O
1,500 29 34 364 369 B-lower_bound
/ 34 35 369 370 I-lower_bound
mcL 35 38 370 373 I-lower_bound

Activated 0 9 374 383 O
partial 10 17 384 391 B-clinical_variable
thromboplastin 18 32 392 406 I-clinical_variable
time 33 37 407 411 I-clinical_variable
( 38 39 412 413 I-clinical_variable
aPTT 39 43 413 417 I-clinical_variable
) 43 44 417 418 I-clinical_variable
within 45 51 419 425 O
1.25 52 56 426 430 B-upper_bound
x 57 58 431 432 I-upper_bound
ULN 59 62 433 436 I-upper_bound
institutional 63 76 437 450 I-upper_bound
limits 77 83 451 457 I-upper_bound
, 83 84 457 458 O
except 85 91 459 465 O
where 92 97 466 471 O
a 98 99 472 473 O
lupus 100 105 474 479 B-chronic_disease
anti 106 110 480 484 B-treatment
- 110 111 484 485 I-treatment
coagulant 111 120 485 494 I-treatment
has 121 124 495 498 O
been 125 129 499 503 O
confirmed 130 139 504 513 O

Adequately 0 10 514 524 O
controlled 11 21 525 535 O
blood 22 27 536 541 B-clinical_variable
pressure 28 36 542 550 I-clinical_variable
( 37 38 551 552 I-clinical_variable
BP 38 40 552 554 I-clinical_variable
) 40 41 554 555 I-clinical_variable
< 42 43 556 557 O
140 44 47 558 561 B-upper_bound
mmHg 48 52 562 566 I-upper_bound
( 53 54 567 568 O
systolic 54 62 568 576 B-clinical_variable
) 62 63 576 577 O
and 64 67 578 581 O
< 68 69 582 583 O
90 70 72 584 586 B-upper_bound
mmHg 73 77 587 591 I-upper_bound
( 78 79 592 593 O
diastolic 79 88 593 602 B-clinical_variable
) 88 89 602 603 O
taken 90 95 604 609 O
in 96 98 610 612 O
the 99 102 613 616 O
clinic 103 109 617 623 O
setting 110 117 624 631 O
by 118 120 632 634 O
a 121 122 635 636 O
medical 123 130 637 644 O
professional 131 143 645 657 O
within 144 150 658 664 O
2 151 152 665 666 B-upper_bound
weeks 153 158 667 672 I-upper_bound
prior 159 164 673 678 I-upper_bound
to 165 167 679 681 O
starting 168 176 682 690 O
study 177 182 691 696 O

Adequately 0 10 697 707 O
controlled 11 21 708 718 O
thyroid 22 29 719 726 O
function 30 38 727 735 O
defined 39 46 736 743 O
by 47 49 744 746 O
free 50 54 747 751 O
T4 55 57 752 754 O
within 58 64 755 761 O
normal 65 71 762 768 O
range 72 77 769 774 O
, 77 78 774 775 O
with 79 83 776 780 O
no 84 86 781 783 O
symptoms 87 95 784 792 O
of 96 98 793 795 O
thyroid 99 106 796 803 B-chronic_disease
dysfunction 107 118 804 815 I-chronic_disease

An 0 2 816 818 O
ultrasound 3 13 819 829 B-treatment
( 14 15 830 831 I-treatment
US 15 17 831 833 I-treatment
) 17 18 833 834 I-treatment
within 19 25 835 841 O
the 26 29 842 845 O
last 30 34 846 850 B-upper_bound
6 35 36 851 852 I-upper_bound
months 37 43 853 859 I-upper_bound
prior 44 49 860 865 I-upper_bound
to 50 52 866 868 O
registration 53 65 869 881 O
will 66 70 882 886 O
be 71 73 887 889 O
required 74 82 890 898 O
to 83 85 899 901 O
document 86 94 902 910 O
that 95 99 911 915 O
it 100 102 916 918 O
is 103 105 919 921 O
= 106 107 922 923 O
< 107 108 923 924 O
5 109 110 925 926 B-upper_bound
cm 111 113 927 929 I-upper_bound

Any 0 3 930 933 O
condition 4 13 934 943 O
that 14 18 944 948 O
, 18 19 948 949 O
in 20 22 950 952 O
the 23 26 953 956 O
opinion 27 34 957 964 O
of 35 37 965 967 O
the 38 41 968 971 O
treating 42 50 972 980 O
investigator 51 63 981 993 O
would 64 69 994 999 O
interfere 70 79 1000 1009 O
with 80 84 1010 1014 O
evaluation 85 95 1015 1025 O
of 96 98 1026 1028 O
the 99 102 1029 1032 O
investigational 103 118 1033 1048 B-treatment
product 119 126 1049 1056 I-treatment
or 127 129 1057 1059 O
interpretation 130 144 1060 1074 O
of 145 147 1075 1077 O
subject 148 155 1078 1085 O
safety 156 162 1086 1092 O
or 163 165 1093 1095 O
study 166 171 1096 1101 O
results 172 179 1102 1109 O

Aspartate 0 9 1110 1119 B-clinical_variable
aminotransferase 10 26 1120 1136 I-clinical_variable
( 27 28 1137 1138 I-clinical_variable
AST 28 31 1138 1141 I-clinical_variable
) 31 32 1141 1142 I-clinical_variable
( 33 34 1143 1144 O
serum 34 39 1144 1149 B-clinical_variable
glutamic 40 48 1150 1158 I-clinical_variable
oxaloacetic 49 60 1159 1170 I-clinical_variable
transaminase 61 73 1171 1183 I-clinical_variable
[ 74 75 1184 1185 I-clinical_variable
SGOT])/alanine 75 89 1185 1199 I-clinical_variable
aminotransferase 90 106 1200 1216 I-clinical_variable
( 107 108 1217 1218 I-clinical_variable
ALT 108 111 1218 1221 I-clinical_variable
) 111 112 1221 1222 I-clinical_variable
( 113 114 1223 1224 O
serum 114 119 1224 1229 B-clinical_variable
glutamate 120 129 1230 1239 I-clinical_variable
pyruvate 130 138 1240 1248 I-clinical_variable
transaminase 139 151 1249 1261 I-clinical_variable
[ 152 153 1262 1263 I-clinical_variable
SGPT 153 157 1263 1267 I-clinical_variable
] 157 158 1267 1268 I-clinical_variable
) 158 159 1268 1269 O
= 160 161 1270 1271 O
< 161 162 1271 1272 O
2.5 163 166 1273 1276 B-upper_bound
x 167 168 1277 1278 I-upper_bound
institutional 169 182 1279 1292 I-upper_bound
ULN 183 186 1293 1296 I-upper_bound

Creatinine 0 10 1297 1307 B-clinical_variable
= 11 12 1308 1309 O
< 12 13 1309 1310 O
1.5 14 17 1311 1314 B-upper_bound
x 18 19 1315 1316 I-upper_bound
ULN 20 23 1317 1320 I-upper_bound

Creatinine 0 10 1321 1331 B-clinical_variable
clearance 11 20 1332 1341 I-clinical_variable
> 21 22 1342 1343 O
= 22 23 1343 1344 O
45 24 26 1345 1347 B-lower_bound
mL 27 29 1348 1350 I-lower_bound
/ 29 30 1350 1351 I-lower_bound
min/1.73 30 38 1351 1359 I-lower_bound
m^2 39 42 1360 1363 I-lower_bound
for 43 46 1364 1367 O
patients 47 55 1368 1376 O
with 56 60 1377 1381 O
creatinine 61 71 1382 1392 B-clinical_variable
levels 72 78 1393 1399 I-clinical_variable
above 79 84 1400 1405 O
institutional 85 98 1406 1419 O
normal 99 105 1420 1426 O

Current 0 7 1427 1434 O
cardiac 8 15 1435 1442 B-chronic_disease
arrhythmia 16 26 1443 1453 I-chronic_disease
requiring 27 36 1454 1463 O
concurrent 37 47 1464 1474 O
use 48 51 1475 1478 O
of 52 54 1479 1481 O
anti 55 59 1482 1486 B-treatment
- 59 60 1486 1487 I-treatment
arrhythmic 60 70 1487 1497 I-treatment
drugs 71 76 1498 1503 I-treatment

Current 0 7 1504 1511 O
use 8 11 1512 1515 O
of 12 14 1516 1518 O
natural 15 22 1519 1526 B-treatment
herbal 23 29 1527 1533 I-treatment
products 30 38 1534 1542 I-treatment
or 39 41 1543 1545 O
other 42 47 1546 1551 O
complementary 48 61 1552 1565 B-treatment
alternative 62 73 1566 1577 I-treatment
medications 74 85 1578 1589 I-treatment
( 86 87 1590 1591 I-treatment
CAM 87 90 1591 1594 I-treatment
) 90 91 1594 1595 I-treatment
or 92 94 1596 1598 O
folk 95 99 1599 1603 O
remedies 100 108 1604 1612 O

Eastern 0 7 1613 1620 B-clinical_variable
Cooperative 8 19 1621 1632 I-clinical_variable
Oncology 20 28 1633 1641 I-clinical_variable
Group 29 34 1642 1647 I-clinical_variable
( 35 36 1648 1649 I-clinical_variable
ECOG 36 40 1649 1653 I-clinical_variable
) 40 41 1653 1654 I-clinical_variable
performance 42 53 1655 1666 I-clinical_variable
status 54 60 1667 1673 I-clinical_variable
0 61 62 1674 1675 B-lower_bound
, 62 63 1675 1676 O
1 64 65 1677 1678 O
or 66 68 1679 1681 O
2 69 70 1682 1683 B-upper_bound
( 71 72 1684 1685 O
Karnofsky 72 81 1685 1694 B-clinical_variable
> 82 83 1695 1696 O
= 83 84 1696 1697 O
50 85 87 1698 1700 B-lower_bound
% 87 88 1700 1701 I-lower_bound
) 88 89 1701 1702 O

Hemoglobin 0 10 1703 1713 B-clinical_variable
> 11 12 1714 1715 O
9 13 14 1716 1717 B-lower_bound
g 15 16 1718 1719 I-lower_bound
/ 16 17 1719 1720 I-lower_bound
dL 17 19 1720 1722 I-lower_bound

History 0 7 1723 1730 O
of 8 10 1731 1733 O
abdominal 11 20 1734 1743 O
fistula 21 28 1744 1751 B-chronic_disease
, 28 29 1751 1752 O
intra 30 35 1753 1758 B-chronic_disease
- 35 36 1758 1759 I-chronic_disease
abdominal 36 45 1759 1768 I-chronic_disease
abscess 46 53 1769 1776 I-chronic_disease
, 53 54 1776 1777 O
or 55 57 1778 1780 O
gastrointestinal 58 74 1781 1797 B-chronic_disease
perforation 75 86 1798 1809 I-chronic_disease
within 87 93 1810 1816 O
the 94 97 1817 1820 O
3 98 99 1821 1822 B-upper_bound
months 100 106 1823 1829 I-upper_bound
prior 107 112 1830 1835 I-upper_bound
to 113 115 1836 1838 O
enrollment 116 126 1839 1849 O

History 0 7 1850 1857 O
of 8 10 1858 1860 O
allergic 11 19 1861 1869 O
reactions 20 29 1870 1879 O
attributed 30 40 1880 1890 O
to 41 43 1891 1893 O
compounds 44 53 1894 1903 O
of 54 56 1904 1906 O
similar 57 64 1907 1914 O
chemical 65 73 1915 1923 O
or 74 76 1924 1926 O
biologic 77 85 1927 1935 O
composition 86 97 1936 1947 O
to 98 100 1948 1950 O
cediranib 101 110 1951 1960 B-treatment
or 111 113 1961 1963 O
olaparib 114 122 1964 1972 B-treatment

History 0 7 1973 1980 O
of 8 10 1981 1983 O
bowel 11 16 1984 1989 B-chronic_disease
obstruction 17 28 1990 2001 I-chronic_disease
within 29 35 2002 2008 O
1 36 37 2009 2010 B-upper_bound
month 38 43 2011 2016 I-upper_bound
prior 44 49 2017 2022 I-upper_bound
to 50 52 2023 2025 O
starting 53 61 2026 2034 O
study 62 67 2035 2040 B-treatment
drugs 68 73 2041 2046 I-treatment

History 0 7 2047 2054 O
of 8 10 2055 2057 O
hemoptysis 11 21 2058 2068 B-chronic_disease
or 22 24 2069 2071 O
any 25 28 2072 2075 O
significant 29 40 2076 2087 O
bleeding 41 49 2088 2096 B-chronic_disease
within 50 56 2097 2103 O
the 57 60 2104 2107 O
last 61 65 2108 2112 B-upper_bound
1 66 67 2113 2114 I-upper_bound
month 68 73 2115 2120 I-upper_bound
prior 74 79 2121 2126 I-upper_bound
to 80 82 2127 2129 O
enrollment 83 93 2130 2140 O

History 0 7 2141 2148 O
of 8 10 2149 2151 O
hypertensive 11 23 2152 2164 B-chronic_disease
crisis 24 30 2165 2171 I-chronic_disease
or 31 33 2172 2174 O
hypertensive 34 46 2175 2187 B-chronic_disease
encephalopathy 47 61 2188 2202 I-chronic_disease
within 62 68 2203 2209 O
3 69 70 2210 2211 B-upper_bound
years 71 76 2212 2217 I-upper_bound
prior 77 82 2218 2223 I-upper_bound
to 83 85 2224 2226 O
registration 86 98 2227 2239 O

History 0 7 2240 2247 O
of 8 10 2248 2250 O
myocardial 11 21 2251 2261 B-chronic_disease
infarction 22 32 2262 2272 I-chronic_disease
within 33 39 2273 2279 O
12 40 42 2280 2282 B-upper_bound
months 43 49 2283 2289 I-upper_bound
( 50 51 2290 2291 O
patients 51 59 2291 2299 O
with 60 64 2300 2304 O
history 65 72 2305 2312 O
of 73 75 2313 2315 O
myocardial 76 86 2316 2326 O
infarction 87 97 2327 2337 O
within 98 104 2338 2344 O
6 105 106 2345 2346 B-upper_bound
months 107 113 2347 2353 I-upper_bound
are 114 117 2354 2357 O
excluded 118 126 2358 2366 O
from 127 131 2367 2371 O
the 132 135 2372 2375 O
study 136 141 2376 2381 O
) 141 142 2381 2382 O

History 0 7 2383 2390 O
of 8 10 2391 2393 O
myocardial 11 21 2394 2404 B-chronic_disease
infarction 22 32 2405 2415 I-chronic_disease
within 33 39 2416 2422 O
6 40 41 2423 2424 B-upper_bound
months 42 48 2425 2431 I-upper_bound
prior 49 54 2432 2437 O
to 55 57 2438 2440 O
registration 58 70 2441 2453 O

History 0 7 2454 2461 O
of 8 10 2462 2464 O
stroke 11 17 2465 2471 B-chronic_disease
or 18 20 2472 2474 O
transient 21 30 2475 2484 B-chronic_disease
ischemic 31 39 2485 2493 I-chronic_disease
attack 40 46 2494 2500 I-chronic_disease
within 47 53 2501 2507 O
6 54 55 2508 2509 B-upper_bound
months 56 62 2510 2516 I-upper_bound
prior 63 68 2517 2522 I-upper_bound
to 69 71 2523 2525 O
registration 72 84 2526 2538 O

Human 0 5 2539 2544 B-chronic_disease
immunodeficiency 6 22 2545 2561 I-chronic_disease
virus 23 28 2562 2567 I-chronic_disease
( 29 30 2568 2569 I-chronic_disease
HIV)-positive 30 43 2569 2582 I-chronic_disease
patients 44 52 2583 2591 O
on 53 55 2592 2594 O
combination 56 67 2595 2606 B-treatment
antiretroviral 68 82 2607 2621 I-treatment
therapy 83 90 2622 2629 I-treatment
are 91 94 2630 2633 O
ineligible 95 105 2634 2644 O
because 106 113 2645 2652 O
of 114 116 2653 2655 O
the 117 120 2656 2659 O
potential 121 130 2660 2669 O
for 131 134 2670 2673 O
pharmacokinetic 135 150 2674 2689 O
interactions 151 163 2690 2702 O
with 164 168 2703 2707 O
cediranib 169 178 2708 2717 B-treatment
or 179 181 2718 2720 O
olaparib 182 190 2721 2729 B-treatment
; 190 191 2729 2730 O
appropriate 192 203 2731 2742 O
studies 204 211 2743 2750 O
will 212 216 2751 2755 O
be 217 219 2756 2758 O
undertaken 220 230 2759 2769 O
in 231 233 2770 2772 O
patients 234 242 2773 2781 O
receiving 243 252 2782 2791 O
combination 253 264 2792 2803 O
antiretroviral 265 279 2804 2818 O
therapy 280 287 2819 2826 O
when 288 292 2827 2831 O
indicated 293 302 2832 2841 O
; 302 303 2841 2842 O
HIV 304 307 2843 2846 O
- 307 308 2846 2847 O
positive 308 316 2847 2855 O
patients 317 325 2856 2864 O
with 326 330 2865 2869 O
undetectable 331 343 2870 2882 O
viral 344 349 2883 2888 O
loads 350 355 2889 2894 O
and 356 359 2895 2898 O
CD4 360 363 2899 2902 B-clinical_variable
counts 364 370 2903 2909 I-clinical_variable
> 371 372 2910 2911 O
300 373 376 2912 2915 B-lower_bound
, 376 377 2915 2916 O
and 378 381 2917 2920 O
not 382 385 2921 2924 O
on 386 388 2925 2927 O
any 389 392 2928 2931 O
antiretroviral 393 407 2932 2946 O
therapy 408 415 2947 2954 O
may 416 419 2955 2958 O
be 420 422 2959 2961 O
allowed 423 430 2962 2969 O
after 431 436 2970 2975 O
discussing 437 447 2976 2986 O
with 448 452 2987 2991 O
the 453 456 2992 2995 O
principle 457 466 2996 3005 O
investigator 467 479 3006 3018 O

International 0 13 3019 3032 B-clinical_variable
normalized 14 24 3033 3043 I-clinical_variable
ration 25 31 3044 3050 I-clinical_variable
( 32 33 3051 3052 I-clinical_variable
INR 33 36 3052 3055 I-clinical_variable
) 36 37 3055 3056 I-clinical_variable
within 38 44 3057 3063 O
1.25 45 49 3064 3068 B-upper_bound
x 50 51 3069 3070 I-upper_bound
ULN 52 55 3071 3074 I-upper_bound
institutional 56 69 3075 3088 I-upper_bound
limits 70 76 3089 3095 I-upper_bound
, 76 77 3095 3096 O
except 78 84 3097 3103 O
where 85 90 3104 3109 O
a 91 92 3110 3111 O
lupus 93 98 3112 3117 O
anti 99 103 3118 3122 O
- 103 104 3122 3123 O
coagulant 104 113 3123 3132 O
has 114 117 3133 3136 O
been 118 122 3137 3141 O
confirmed 123 132 3142 3151 O

Leukocytes 0 10 3152 3162 B-clinical_variable
> 11 12 3163 3164 O
= 12 13 3164 3165 O
3,000 14 19 3166 3171 B-lower_bound
/ 19 20 3171 3172 I-lower_bound
mcL 20 23 3172 3175 I-lower_bound

Life 0 4 3176 3180 B-clinical_variable
expectancy 5 15 3181 3191 I-clinical_variable
of 16 18 3192 3194 O
> 19 20 3195 3196 O
= 20 21 3196 3197 O
4 22 23 3198 3199 B-lower_bound
months 24 30 3200 3206 I-lower_bound

Must 0 4 3207 3211 O
have 5 9 3212 3216 O
received 10 18 3217 3225 O
at 19 21 3226 3228 O
least 22 27 3229 3234 O
one 28 31 3235 3238 B-lower_bound
line 32 36 3239 3243 O
of 37 39 3244 3246 O
standard 40 48 3247 3255 B-treatment
systemic 49 57 3256 3264 I-treatment
treatment 58 67 3265 3274 I-treatment
for 68 71 3275 3278 O
locally 72 79 3279 3286 O
advanced 80 88 3287 3295 B-cancer
or 89 91 3296 3298 O
metastatic 92 102 3299 3309 B-cancer
disease 103 110 3310 3317 I-cancer
setting 111 118 3318 3325 O
of 119 121 3326 3328 O
the 122 125 3329 3332 O
respective 126 136 3333 3343 O
tumor 137 142 3344 3349 B-cancer
type 143 147 3350 3354 O
; 147 148 3354 3355 O
for 149 152 3356 3359 O
NSCLC 153 158 3360 3365 B-cancer
, 158 159 3365 3366 O
it 160 162 3367 3369 O
is 163 165 3370 3372 O
either 166 172 3373 3379 O
PD-1 173 177 3380 3384 B-treatment
/ 177 178 3384 3385 I-treatment
PD 178 180 3385 3387 I-treatment
- 180 181 3387 3388 I-treatment
L1 181 183 3388 3390 I-treatment
inhibitor 184 193 3391 3400 I-treatment
, 193 194 3400 3401 O
or 195 197 3402 3404 O
platinum 198 206 3405 3413 B-treatment
- 206 207 3413 3414 I-treatment
containing 207 217 3414 3424 I-treatment
chemotherapy 218 230 3425 3437 I-treatment
, 230 231 3437 3438 O
or 232 234 3439 3441 O
an 235 237 3442 3444 O
EGFR 238 242 3445 3449 B-treatment
tyrosine 243 251 3450 3458 I-treatment
kinase 252 258 3459 3465 I-treatment
inhibitor 259 268 3466 3475 I-treatment
or 269 271 3476 3478 O
an 272 274 3479 3481 O
ALK 275 278 3482 3485 B-treatment
inhibitor 279 288 3486 3495 I-treatment
if 289 291 3496 3498 O
sensitizing 292 303 3499 3510 O
mutation 304 312 3511 3519 O
present 313 320 3520 3527 O
; 320 321 3527 3528 O
TNBC 322 326 3529 3533 B-cancer
: 326 327 3533 3534 O
platinum 328 336 3535 3543 O
- 336 337 3543 3544 O
containing 337 347 3544 3554 O
chemotherapy 348 360 3555 3567 O
; 360 361 3567 3568 O
PDAC 362 366 3569 3573 O
: 366 367 3573 3574 O
fluorouracil 368 380 3575 3587 B-treatment
( 381 382 3588 3589 I-treatment
5 382 383 3589 3590 I-treatment
- 383 384 3590 3591 I-treatment
FU- 384 387 3591 3594 I-treatment
) 387 388 3594 3595 I-treatment
, 388 389 3595 3596 O
gemcitabine- 390 402 3597 3609 B-treatment
, 402 403 3609 3610 O
or 404 406 3611 3613 O
taxane 407 413 3614 3620 B-treatment
- 413 414 3620 3621 I-treatment
containing 414 424 3621 3631 I-treatment
chemotherapy 425 437 3632 3644 I-treatment
either 438 444 3645 3651 O
with 445 449 3652 3656 O
or 450 452 3657 3659 O
without 453 460 3660 3667 O
radiation 461 470 3668 3677 B-treatment
therapy 471 478 3678 3685 I-treatment
; 478 479 3685 3686 O
SCLC 480 484 3687 3691 O
: 484 485 3691 3692 O
platinum 486 494 3693 3701 O
- 494 495 3701 3702 O
containing 495 505 3702 3712 O
chemotherapy 506 518 3713 3725 O
for 519 522 3726 3729 O
limited 523 530 3730 3737 O
or 531 533 3738 3740 O
extensive 534 543 3741 3750 O
stage 544 549 3751 3756 O
disease 550 557 3757 3764 O

NYHA 0 4 3765 3769 B-clinical_variable
classification 5 19 3770 3784 O
of 20 22 3785 3787 O
III 23 26 3788 3791 B-lower_bound
or 27 29 3792 3794 O
IV 30 32 3795 3797 B-upper_bound

Participants 0 12 3798 3810 O
receiving 13 22 3811 3820 O
any 23 26 3821 3824 O
medications 27 38 3825 3836 B-treatment
or 39 41 3837 3839 O
substances 42 52 3840 3850 O
that 53 57 3851 3855 O
are 58 61 3856 3859 O
strong 62 68 3860 3866 O
inhibitors 69 79 3867 3877 O
or 80 82 3878 3880 O
inducers 83 91 3881 3889 O
of 92 94 3890 3892 O
cytochrome 95 105 3893 3903 B-treatment
P450 106 110 3904 3908 I-treatment
, 110 111 3908 3909 O
family 112 118 3910 3916 B-treatment
3 119 120 3917 3918 I-treatment
, 120 121 3918 3919 O
subfamily 122 131 3920 3929 B-treatment
A 132 133 3930 3931 I-treatment
, 133 134 3931 3932 O
polypeptide 135 146 3933 3944 B-treatment
4 147 148 3945 3946 I-treatment
( 149 150 3947 3948 I-treatment
CYP3A4 150 156 3948 3954 I-treatment
) 156 157 3954 3955 I-treatment
are 158 161 3956 3959 O
ineligible 162 172 3960 3970 O

Patients 0 8 3971 3979 O
may 9 12 3980 3983 O
not 13 16 3984 3987 O
have 17 21 3988 3992 O
current 22 29 3993 4000 O
dependency 30 40 4001 4011 O
on 41 43 4012 4014 O
intravenous 44 55 4015 4026 B-treatment
( 56 57 4027 4028 I-treatment
IV 57 59 4028 4030 I-treatment
) 59 60 4030 4031 I-treatment
hydration 61 70 4032 4041 I-treatment
or 71 73 4042 4044 O
total 74 79 4045 4050 B-treatment
parenteral 80 90 4051 4061 I-treatment
nutrition 91 100 4062 4071 I-treatment
( 101 102 4072 4073 I-treatment
TPN 102 105 4073 4076 I-treatment
) 105 106 4076 4077 I-treatment

Patients 0 8 4078 4086 O
may 9 12 4087 4090 O
not 13 16 4091 4094 O
have 17 21 4095 4099 O
evidence 22 30 4100 4108 O
of 31 33 4109 4111 O
coagulopathy 34 46 4112 4124 B-chronic_disease
or 47 49 4125 4127 O
bleeding 50 58 4128 4136 B-chronic_disease
diathesis 59 68 4137 4146 I-chronic_disease

Patients 0 8 4147 4155 O
may 9 12 4156 4159 O
not 13 16 4160 4163 O
have 17 21 4164 4168 O
features 22 30 4169 4177 O
suggestive 31 41 4178 4188 O
of 42 44 4189 4191 O
myelodysplastic 45 60 4192 4207 B-cancer
syndrome 61 69 4208 4216 I-cancer
( 70 71 4217 4218 I-cancer
MDS 71 74 4218 4221 I-cancer
) 74 75 4221 4222 I-cancer
or 76 78 4223 4225 O
acute 79 84 4226 4231 B-cancer
myelogenous 85 96 4232 4243 I-cancer
leukemia 97 105 4244 4252 I-cancer
( 106 107 4253 4254 I-cancer
AML 107 110 4254 4257 I-cancer
) 110 111 4257 4258 I-cancer
on 112 114 4259 4261 O
peripheral 115 125 4262 4272 O
blood 126 131 4273 4278 O
smear 132 137 4279 4284 O
or 138 140 4285 4287 O
bone 141 145 4288 4292 O
marrow 146 152 4293 4299 O
biopsy 153 159 4300 4306 B-treatment

Patients 0 8 4307 4315 O
must 9 13 4316 4320 O
be 14 16 4321 4323 O
able 17 21 4324 4328 O
to 22 24 4329 4331 O
tolerate 25 33 4332 4340 O
oral 34 38 4341 4345 B-treatment
medications 39 50 4346 4357 I-treatment
and 51 54 4358 4361 O
not 55 58 4362 4365 O
have 59 63 4366 4370 O
gastrointestinal 64 80 4371 4387 B-chronic_disease
illnesses 81 90 4388 4397 I-chronic_disease
that 91 95 4398 4402 O
would 96 101 4403 4408 O
preclude 102 110 4409 4417 O
absorption 111 121 4418 4428 O
of 122 124 4429 4431 O
cediranib 125 134 4432 4441 B-treatment
or 135 137 4442 4444 O
olaparib 138 146 4445 4453 B-treatment

Patients 0 8 4454 4462 O
must 9 13 4463 4467 O
have 14 18 4468 4472 O
histologically 19 33 4473 4487 O
confirmed 34 43 4488 4497 O
, 43 44 4497 4498 O
metastatic 45 55 4499 4509 O
or 56 58 4510 4512 O
unresectable 59 71 4513 4525 O
malignancy 72 82 4526 4536 B-cancer
of 83 85 4537 4539 O
the 86 89 4540 4543 O
following 90 99 4544 4553 O
types 100 105 4554 4559 O
: 105 106 4559 4560 O
( 107 108 4561 4562 O
a 108 109 4562 4563 O
) 109 110 4563 4564 O
non 111 114 4565 4568 B-cancer
- 114 115 4568 4569 I-cancer
small 115 120 4569 4574 I-cancer
cell 121 125 4575 4579 I-cancer
lung 126 130 4580 4584 I-cancer
cancer 131 137 4585 4591 I-cancer
( 138 139 4592 4593 I-cancer
NSCLC 139 144 4593 4598 I-cancer
) 144 145 4598 4599 I-cancer
, 145 146 4599 4600 O
( 147 148 4601 4602 O
b 148 149 4602 4603 O
) 149 150 4603 4604 O
triple 151 157 4605 4611 B-cancer
- 157 158 4611 4612 I-cancer
negative 158 166 4612 4620 I-cancer
breast 167 173 4621 4627 I-cancer
cancer 174 180 4628 4634 I-cancer
( 181 182 4635 4636 I-cancer
TNBC 182 186 4636 4640 I-cancer
; 186 187 4640 4641 O
defined 188 195 4642 4649 O
by 196 198 4650 4652 O
estrogen 199 207 4653 4661 B-clinical_variable
receptor 208 216 4662 4670 I-clinical_variable
[ 217 218 4671 4672 I-clinical_variable
ER 218 220 4672 4674 I-clinical_variable
] 220 221 4674 4675 I-clinical_variable
< 222 223 4676 4677 O
1 224 225 4678 4679 B-upper_bound
% 225 226 4679 4680 I-upper_bound
, 226 227 4680 4681 O
progesterone 228 240 4682 4694 B-clinical_variable
receptor 241 249 4695 4703 I-clinical_variable
[ 250 251 4704 4705 I-clinical_variable
PR 251 253 4705 4707 I-clinical_variable
] 253 254 4707 4708 I-clinical_variable
< 255 256 4709 4710 O
1 257 258 4711 4712 O
% 258 259 4712 4713 O
and 260 263 4714 4717 O
HER2 264 268 4718 4722 O
1 269 270 4723 4724 O
+ 270 271 4724 4725 O
or 272 274 4726 4728 O
less 275 279 4729 4733 O
by 280 282 4734 4736 O
immunohistochemistry 283 303 4737 4757 B-treatment
[ 304 305 4758 4759 I-treatment
IHC 305 308 4759 4762 I-treatment
] 308 309 4762 4763 I-treatment
; 309 310 4763 4764 O
if 311 313 4765 4767 O
HER-2 314 319 4768 4773 O
expression 320 330 4774 4784 O
is 331 333 4785 4787 O
2 334 335 4788 4789 O
+ 335 336 4789 4790 O
, 336 337 4790 4791 O
a 338 339 4792 4793 O
negative 340 348 4794 4802 O
fluorescence 349 361 4803 4815 B-treatment
in 362 364 4816 4818 I-treatment
situ 365 369 4819 4823 I-treatment
hybridization 370 383 4824 4837 I-treatment
[ 384 385 4838 4839 I-treatment
FISH 385 389 4839 4843 I-treatment
] 389 390 4843 4844 I-treatment
testing 391 398 4845 4852 O
is 399 401 4853 4855 O
required 402 410 4856 4864 O
) 410 411 4864 4865 O
( 412 413 4866 4867 O
c 413 414 4867 4868 O
) 414 415 4868 4869 O
pancreatic 416 426 4870 4880 B-cancer
adenocarcinoma 427 441 4881 4895 I-cancer
( 442 443 4896 4897 I-cancer
PDAC 443 447 4897 4901 I-cancer
) 447 448 4901 4902 I-cancer
, 448 449 4902 4903 O
or 450 452 4904 4906 O
( 453 454 4907 4908 O
d 454 455 4908 4909 O
) 455 456 4909 4910 O
small 457 462 4911 4916 B-cancer
cell 463 467 4917 4921 I-cancer
lung 468 472 4922 4926 I-cancer
cancer 473 479 4927 4933 I-cancer
( 480 481 4934 4935 I-cancer
SCLC 481 485 4935 4939 I-cancer
) 485 486 4939 4940 I-cancer

Patients 0 8 4941 4949 O
must 9 13 4950 4954 O
have 14 18 4955 4959 O
measurable 19 29 4960 4970 O
disease 30 37 4971 4978 O
by 38 40 4979 4981 O
Response 41 49 4982 4990 O
Evaluation 50 60 4991 5001 O
Criteria 61 69 5002 5010 O
in 70 72 5011 5013 O
Solid 73 78 5014 5019 B-cancer
Tumors 79 85 5020 5026 I-cancer
( 86 87 5027 5028 O
RECIST 87 93 5028 5034 O
) 93 94 5034 5035 O
version 95 102 5036 5043 O
( 103 104 5044 5045 O
v)1.1 104 109 5045 5050 O

Patients 0 8 5051 5059 O
should 9 15 5060 5066 O
not 16 19 5067 5070 O
have 20 24 5071 5075 O
received 25 33 5076 5084 O
any 34 37 5085 5088 O
other 38 43 5089 5094 O
investigational 44 59 5095 5110 B-treatment
agents 60 66 5111 5117 I-treatment
within 67 73 5118 5124 O
the 74 77 5125 5128 O
past 78 82 5129 5133 B-upper_bound
4 83 84 5134 5135 I-upper_bound
weeks 85 90 5136 5141 I-upper_bound

Patients 0 8 5142 5150 O
who 9 12 5151 5154 O
have 13 17 5155 5159 O
had 18 21 5160 5163 O
chemotherapy 22 34 5164 5176 B-treatment
or 35 37 5177 5179 O
RT 38 40 5180 5182 B-treatment
within 41 47 5183 5189 O
3 48 49 5190 5191 B-upper_bound
weeks 50 55 5192 5197 I-upper_bound
prior 56 61 5198 5203 I-upper_bound
to 62 64 5204 5206 O
start 65 70 5207 5212 O
of 71 73 5213 5215 O
the 74 77 5216 5219 O
study 78 83 5220 5225 B-treatment
agents 84 90 5226 5232 I-treatment
, 90 91 5232 5233 O
or 92 94 5234 5236 O
those 95 100 5237 5242 O
who 101 104 5243 5246 O
have 105 109 5247 5251 O
not 110 113 5252 5255 O
recovered 114 123 5256 5265 O
from 124 128 5266 5270 O
adverse 129 136 5271 5278 O
events 137 143 5279 5285 O
due 144 147 5286 5289 O
to 148 150 5290 5292 O
agents 151 157 5293 5299 O
administered 158 170 5300 5312 O
more 171 175 5313 5317 O
than 176 180 5318 5322 O
3 181 182 5323 5324 B-lower_bound
weeks 183 188 5325 5330 I-lower_bound
earlier 189 196 5331 5338 I-lower_bound

Patients 0 8 5339 5347 O
who 9 12 5348 5351 O
have 13 17 5352 5356 O
received 18 26 5357 5365 O
prior 27 32 5366 5371 B-treatment
inhibitor 33 42 5372 5381 I-treatment
of 43 45 5382 5384 I-treatment
VEGF 46 50 5385 5389 I-treatment
signaling 51 60 5390 5399 I-treatment
and 61 64 5400 5403 I-treatment
a 65 66 5404 5405 I-treatment
poly 67 71 5406 5410 I-treatment
( 72 73 5411 5412 I-treatment
ADP 73 76 5412 5415 I-treatment
- 76 77 5415 5416 I-treatment
ribose 77 83 5416 5422 I-treatment
) 83 84 5422 5423 I-treatment
polymerases 85 96 5424 5435 I-treatment
( 97 98 5436 5437 I-treatment
PARP 98 102 5437 5441 I-treatment
) 102 103 5441 5442 I-treatment
inhibitor 104 113 5443 5452 I-treatment
administered 114 126 5453 5465 O
in 127 129 5466 5468 O
combination 130 141 5469 5480 O
; 141 142 5480 5481 O
unless 143 149 5482 5488 O
administered 150 162 5489 5501 O
in 163 165 5502 5504 O
combination 166 177 5505 5516 O
, 177 178 5516 5517 O
patients 179 187 5518 5526 O
who 188 191 5527 5530 O
received 192 200 5531 5539 O
a 201 202 5540 5541 O
prior 203 208 5542 5547 B-treatment
PARP 209 213 5548 5552 I-treatment
inhibitor 214 223 5553 5562 I-treatment
or 224 226 5563 5565 O
a 227 228 5566 5567 O
prior 229 234 5568 5573 B-treatment
VEGF 235 239 5574 5578 I-treatment
- 239 240 5578 5579 I-treatment
signaling 240 249 5579 5588 I-treatment
inhibitor 250 259 5589 5598 I-treatment
agent 260 265 5599 5604 O
are 266 269 5605 5608 O
allowed 270 277 5609 5616 O
after 278 283 5617 5622 O
discussing 284 294 5623 5633 O
with 295 299 5634 5638 O
the 300 303 5639 5642 O
PI 304 306 5643 5645 O

Patients 0 8 5646 5654 O
who 9 12 5655 5658 O
have 13 17 5659 5663 O
the 18 21 5664 5667 O
following 22 31 5668 5677 O
risk 32 36 5678 5682 O
factors 37 44 5683 5690 O
are 45 48 5691 5694 O
considered 49 59 5695 5705 O
to 60 62 5706 5708 O
be 63 65 5709 5711 O
at 66 68 5712 5714 O
increased 69 78 5715 5724 O
risk 79 83 5725 5729 O
for 84 87 5730 5733 O
cardiac 88 95 5734 5741 O
toxicities 96 106 5742 5752 O
, 106 107 5752 5753 O
and 108 111 5754 5757 O
must 112 116 5758 5762 O
have 117 121 5763 5767 O
documented 122 132 5768 5778 O
left 133 137 5779 5783 B-clinical_variable
ventricular 138 149 5784 5795 I-clinical_variable
ejection 150 158 5796 5804 I-clinical_variable
fraction 159 167 5805 5813 I-clinical_variable
( 168 169 5814 5815 I-clinical_variable
LVEF 169 173 5815 5819 I-clinical_variable
) 173 174 5819 5820 I-clinical_variable
by 175 177 5821 5823 O
echocardiogram 178 192 5824 5838 B-treatment
greater 193 200 5839 5846 O
than 201 205 5847 5851 O
institution 206 217 5852 5863 O
's 217 219 5863 5865 O
lower 220 225 5866 5871 O
limit 226 231 5872 5877 O
of 232 234 5878 5880 O
normal 235 241 5881 5887 O
( 242 243 5888 5889 O
or 243 245 5889 5891 O
55 246 248 5892 5894 B-lower_bound
% 248 249 5894 5895 I-lower_bound
if 250 252 5896 5898 O
threshold 253 262 5899 5908 O
for 263 266 5909 5912 O
normal 267 273 5913 5919 O
not 274 277 5920 5923 O
otherwise 278 287 5924 5933 O
specified 288 297 5934 5943 O
by 298 300 5944 5946 O
institutional 301 314 5947 5960 O
guidelines 315 325 5961 5971 O
) 325 326 5971 5972 O
obtained 327 335 5973 5981 O
within 336 342 5982 5988 O
3 343 344 5989 5990 B-upper_bound
months 345 351 5991 5997 I-upper_bound

Patients 0 8 5998 6006 O
with 9 13 6007 6011 O
concomitant 14 25 6012 6023 O
or 26 28 6024 6026 O
prior 29 34 6027 6032 B-cancer
invasive 35 43 6033 6041 I-cancer
malignancies 44 56 6042 6054 I-cancer
within 57 63 6055 6061 O
the 64 67 6062 6065 O
past 68 72 6066 6070 B-upper_bound
3 73 74 6071 6072 I-upper_bound
years 75 80 6073 6078 I-upper_bound

Patients 0 8 6079 6087 O
with 9 13 6088 6092 O
untreated 14 23 6093 6102 O
brain 24 29 6103 6108 B-cancer
metastases 30 40 6109 6119 I-cancer
, 40 41 6119 6120 O
spinal 42 48 6121 6127 O
cord 49 53 6128 6132 O
compression 54 65 6133 6144 O
, 65 66 6144 6145 O
or 67 69 6146 6148 O
evidence 70 78 6149 6157 O
of 79 81 6158 6160 O
symptomatic 82 93 6161 6172 O
brain 94 99 6173 6178 O
metastases 100 110 6179 6189 O
or 111 113 6190 6192 O
leptomeningeal 114 128 6193 6207 B-cancer
disease 129 136 6208 6215 I-cancer
as 137 139 6216 6218 O
noted 140 145 6219 6224 O
on 146 148 6225 6227 O
computed 149 157 6228 6236 B-treatment
tomography 158 168 6237 6247 I-treatment
( 169 170 6248 6249 I-treatment
CT 170 172 6249 6251 I-treatment
) 172 173 6251 6252 I-treatment
or 174 176 6253 6255 O
magnetic 177 185 6256 6264 B-treatment
resonance 186 195 6265 6274 I-treatment
imaging 196 203 6275 6282 I-treatment
( 204 205 6283 6284 I-treatment
MRI 205 208 6284 6287 I-treatment
) 208 209 6287 6288 I-treatment
scans 210 215 6289 6294 I-treatment
should 216 222 6295 6301 O
be 223 225 6302 6304 O
excluded 226 234 6305 6313 O
from 235 239 6314 6318 O
this 240 244 6319 6323 O
clinical 245 253 6324 6332 O
trial 254 259 6333 6338 O
, 259 260 6338 6339 O
since 261 266 6340 6345 O
neurologic 267 277 6346 6356 B-chronic_disease
dysfunction 278 289 6357 6368 I-chronic_disease
may 290 293 6369 6372 O
confound 294 302 6373 6381 O
the 303 306 6382 6385 O
evaluation 307 317 6386 6396 O
of 318 320 6397 6399 O
neurologic 321 331 6400 6410 O
and 332 335 6411 6414 O
other 336 341 6415 6420 O
adverse 342 349 6421 6428 O
events 350 356 6429 6435 O
( 357 358 6436 6437 O
AEs 358 361 6437 6440 O
) 361 362 6440 6441 O

Platelets 0 9 6442 6451 B-clinical_variable
> 10 11 6452 6453 O
= 11 12 6453 6454 O
100,000 13 20 6455 6462 B-lower_bound
/ 20 21 6462 6463 I-lower_bound
mcL 21 24 6463 6466 I-lower_bound

Pregnant 0 8 6467 6475 B-pregnancy
women 9 14 6476 6481 B-gender
are 15 18 6482 6485 O
excluded 19 27 6486 6494 O
from 28 32 6495 6499 O
this 33 37 6500 6504 O
study 38 43 6505 6510 O
because 44 51 6511 6518 O
olaparib 52 60 6519 6527 B-treatment
and 61 64 6528 6531 O
cediranib 65 74 6532 6541 B-treatment
have 75 79 6542 6546 O
the 80 83 6547 6550 O
potential 84 93 6551 6560 O
for 94 97 6561 6564 O
teratogenic 98 109 6565 6576 O
or 110 112 6577 6579 O
abortifacient 113 126 6580 6593 O
effects 127 134 6594 6601 O
; 134 135 6601 6602 O
due 136 139 6603 6606 O
to 140 142 6607 6609 O
the 143 146 6610 6613 O
fact 147 151 6614 6618 O
that 152 156 6619 6623 O
there 157 162 6624 6629 O
is 163 165 6630 6632 O
an 166 168 6633 6635 O
unknown 169 176 6636 6643 O
but 177 180 6644 6647 O
potential 181 190 6648 6657 O
risk 191 195 6658 6662 O
for 196 199 6663 6666 O
adverse 200 207 6667 6674 O
events 208 214 6675 6681 O
in 215 217 6682 6684 O
nursing 218 225 6685 6692 O
infants 226 233 6693 6700 O
secondary 234 243 6701 6710 O
to 244 246 6711 6713 O
treatment 247 256 6714 6723 B-treatment
of 257 259 6724 6726 O
the 260 263 6727 6730 O
mother 264 270 6731 6737 O
with 271 275 6738 6742 O
olaparib 276 284 6743 6751 O
and 285 288 6752 6755 O
cediranib 289 298 6756 6765 O
, 298 299 6765 6766 O
breastfeeding 300 313 6767 6780 O
should 314 320 6781 6787 O
be 321 323 6788 6790 O
discontinued 324 336 6791 6803 O
if 337 339 6804 6806 O
the 340 343 6807 6810 O
mother 344 350 6811 6817 O
is 351 353 6818 6820 O
treated 354 361 6821 6828 O
with 362 366 6829 6833 O
cediranib 367 376 6834 6843 O
and 377 380 6844 6847 O
olaparib 381 389 6848 6856 O

Presence 0 8 6857 6865 O
of 9 11 6866 6868 O
cavitation 12 22 6869 6879 B-chronic_disease
of 23 25 6880 6882 I-chronic_disease
central 26 33 6883 6890 I-chronic_disease
pulmonary 34 43 6891 6900 I-chronic_disease
lesion 44 50 6901 6907 I-chronic_disease

Prior 0 5 6908 6913 B-treatment
treatment 6 15 6914 6923 I-treatment
with 16 20 6924 6928 I-treatment
anthracyclines 21 35 6929 6943 I-treatment

Prior 0 5 6944 6949 B-treatment
treatment 6 15 6950 6959 I-treatment
with 16 20 6960 6964 I-treatment
trastuzumab 21 32 6965 6976 I-treatment

The 0 3 6977 6980 O
effects 4 11 6981 6988 O
of 12 14 6989 6991 O
cediranib 15 24 6992 7001 B-treatment
and 25 28 7002 7005 O
olaparib 29 37 7006 7014 B-treatment
on 38 40 7015 7017 O
the 41 44 7018 7021 O
developing 45 55 7022 7032 O
human 56 61 7033 7038 O
fetus 62 67 7039 7044 O
are 68 71 7045 7048 O
unknown 72 79 7049 7056 O
; 79 80 7056 7057 O
for 81 84 7058 7061 O
this 85 89 7062 7066 O
reason 90 96 7067 7073 O
, 96 97 7073 7074 O
women 98 103 7075 7080 B-gender
of 104 106 7081 7083 O
child 107 112 7084 7089 O
- 112 113 7089 7090 O
bearing 113 120 7090 7097 O
potential 121 130 7098 7107 O
and 131 134 7108 7111 O
men 135 138 7112 7115 O
must 139 143 7116 7120 O
agree 144 149 7121 7126 B-contraception_consent
to 150 152 7127 7129 I-contraception_consent
use 153 156 7130 7133 I-contraception_consent
adequate 157 165 7134 7142 I-contraception_consent
contraception 166 179 7143 7156 I-contraception_consent
( 180 181 7157 7158 O
hormonal 181 189 7158 7166 B-contraception_consent
or 190 192 7167 7169 O
barrier 193 200 7170 7177 B-contraception_consent
method 201 207 7178 7184 I-contraception_consent
of 208 210 7185 7187 I-contraception_consent
birth 211 216 7188 7193 I-contraception_consent
control 217 224 7194 7201 I-contraception_consent
; 224 225 7201 7202 O
abstinence 226 236 7203 7213 B-contraception_consent
) 236 237 7213 7214 O
prior 238 243 7215 7220 O
to 244 246 7221 7223 O
study 247 252 7224 7229 O
entry 253 258 7230 7235 O
and 259 262 7236 7239 O
for 263 266 7240 7243 O
the 267 270 7244 7247 O
duration 271 279 7248 7256 O
of 280 282 7257 7259 O
study 283 288 7260 7265 O
participation 289 302 7266 7279 O

The 0 3 7280 7283 O
lesions 4 11 7284 7291 O
have 12 16 7292 7296 O
improved 17 25 7297 7305 O
or 26 28 7306 7308 O
remained 29 37 7309 7317 O
stable 38 44 7318 7324 O
radiographically 45 61 7325 7341 B-treatment
and 62 65 7342 7345 O
clinically 66 76 7346 7356 O
for 77 80 7357 7360 O
at 81 83 7361 7363 O
least 84 89 7364 7369 O
6 90 91 7370 7371 B-lower_bound
weeks 92 97 7372 7377 I-lower_bound
after 98 103 7378 7383 I-lower_bound
completion 104 114 7384 7394 O
of 115 117 7395 7397 O
brain 118 123 7398 7403 B-treatment
irradiation 124 135 7404 7415 I-treatment
or 136 138 7416 7418 O
stereotactic 139 151 7419 7431 B-treatment
brain 152 157 7432 7437 I-treatment
radiosurgery 158 170 7438 7450 I-treatment
and 171 174 7451 7454 O
off 175 178 7455 7458 O
steroids 179 187 7459 7467 B-treatment
for 188 191 7468 7471 O
at 192 194 7472 7474 O
least 195 200 7475 7480 O
6 201 202 7481 7482 O
weeks 203 208 7483 7488 O

Total 0 5 7489 7494 B-clinical_variable
bilirubin 6 15 7495 7504 I-clinical_variable
= 16 17 7505 7506 O
< 17 18 7506 7507 O
1.5 19 22 7508 7511 B-upper_bound
x 23 24 7512 7513 I-upper_bound
the 25 28 7514 7517 I-upper_bound
institutional 29 42 7518 7531 I-upper_bound
upper 43 48 7532 7537 I-upper_bound
limit 49 54 7538 7543 I-upper_bound
of 55 57 7544 7546 I-upper_bound
normal 58 64 7547 7553 I-upper_bound
( 65 66 7554 7555 I-upper_bound
ULN 66 69 7555 7558 I-upper_bound
) 69 70 7558 7559 I-upper_bound

Toxicities 0 10 7560 7570 O
of 11 13 7571 7573 O
prior 14 19 7574 7579 B-treatment
therapy 20 27 7580 7587 I-treatment
( 28 29 7588 7589 O
except 29 35 7589 7595 O
alopecia 36 44 7596 7604 B-chronic_disease
) 44 45 7604 7605 O
should 46 52 7606 7612 O
be 53 55 7613 7615 O
resolved 56 64 7616 7624 O
to 65 67 7625 7627 O
= 68 69 7628 7629 O
< 69 70 7629 7630 O
grade 71 76 7631 7636 B-upper_bound
1 77 78 7637 7638 I-upper_bound
as 79 81 7639 7641 O
per 82 85 7642 7645 O
National 86 94 7646 7654 O
Cancer 95 101 7655 7661 O
Institute 102 111 7662 7671 O
( 112 113 7672 7673 O
NCI)-Common 113 124 7673 7684 O
Terminology 125 136 7685 7696 O
Criteria 137 145 7697 7705 O
for 146 149 7706 7709 O
Adverse 150 157 7710 7717 O
Events 158 164 7718 7724 O
( 165 166 7725 7726 O
CTCAE 166 171 7726 7731 O
) 171 172 7731 7732 O
version 173 180 7733 7740 O

Uncontrolled 0 12 7741 7753 O
intercurrent 13 25 7754 7766 O
illness 26 33 7767 7774 O
including 34 43 7775 7784 O
, 43 44 7784 7785 O
but 45 48 7786 7789 O
not 49 52 7790 7793 O
limited 53 60 7794 7801 O
to 61 63 7802 7804 O
, 63 64 7804 7805 O
ongoing 65 72 7806 7813 O
or 73 75 7814 7816 O
active 76 82 7817 7823 B-chronic_disease
infection 83 92 7824 7833 I-chronic_disease
, 92 93 7833 7834 O
symptomatic 94 105 7835 7846 O
congestive 106 116 7847 7857 B-chronic_disease
heart 117 122 7858 7863 I-chronic_disease
failure 123 130 7864 7871 I-chronic_disease
, 130 131 7871 7872 O
unstable 132 140 7873 7881 B-chronic_disease
angina 141 147 7882 7888 I-chronic_disease
pectoris 148 156 7889 7897 I-chronic_disease
, 156 157 7897 7898 O
cardiac 158 165 7899 7906 B-chronic_disease
arrhythmia 166 176 7907 7917 I-chronic_disease
, 176 177 7917 7918 O
or 178 180 7919 7921 O
psychiatric 181 192 7922 7933 B-chronic_disease
illness 193 200 7934 7941 I-chronic_disease
/ 200 201 7941 7942 I-chronic_disease
social 201 207 7942 7948 I-chronic_disease
situations 208 218 7949 7959 I-chronic_disease
that 219 223 7960 7964 O
would 224 229 7965 7970 O
limit 230 235 7971 7976 O
compliance 236 246 7977 7987 O
with 247 251 7988 7992 O
study 252 257 7993 7998 O
requirements 258 270 7999 8011 O

brain 0 5 8012 8017 B-treatment
MRI 6 9 8018 8021 I-treatment
( 10 11 8022 8023 O
or 11 13 8023 8025 O
CT 14 16 8026 8028 B-treatment
if 17 19 8029 8031 O
MRI 20 23 8032 8035 O
contraindicated 24 39 8036 8051 O
) 39 40 8051 8052 O
is 41 43 8053 8055 O
required 44 52 8056 8064 O
for 53 56 8065 8068 O
PDAC 57 61 8069 8073 O
if 62 64 8074 8076 O
clinically 65 75 8077 8087 O
suspected 76 85 8088 8097 O
by 86 88 8098 8100 O
patient 89 96 8101 8108 O
's 96 98 8108 8110 O
symptoms 99 107 8111 8119 O
or 108 110 8120 8122 O
neurological 111 123 8123 8135 O
exam 124 128 8136 8140 O
; 128 129 8140 8141 O
should 130 136 8142 8148 O
patient 137 144 8149 8156 O
found 145 150 8157 8162 O
to 151 153 8163 8165 O
have 154 158 8166 8170 O
brain 159 164 8171 8176 B-cancer
metastasis 165 175 8177 8187 I-cancer
, 175 176 8187 8188 O
treatment 177 186 8189 8198 B-treatment
of 187 189 8199 8201 O
brain 190 195 8202 8207 O
metastasis 196 206 8208 8218 O
must 207 211 8219 8223 O
precede 212 219 8224 8231 O
the 220 223 8232 8235 O
participation 224 237 8236 8249 O
in 238 240 8250 8252 O
this 241 245 8253 8257 O
study 246 251 8258 8263 O

dihydropyridine 0 15 8264 8279 B-treatment
calcium 16 23 8280 8287 I-treatment
- 23 24 8287 8288 I-treatment
channel 24 31 8288 8295 I-treatment
blockers 32 40 8296 8304 I-treatment
are 41 44 8305 8308 O
permitted 45 54 8309 8318 O
for 55 58 8319 8322 O
management 59 69 8323 8333 O
of 70 72 8334 8336 O
hypertension 73 85 8337 8349 B-chronic_disease

given 0 5 8350 8355 O
the 6 9 8356 8359 O
increases 10 19 8360 8369 O
risk 20 24 8370 8374 O
of 25 27 8375 8377 O
serious 28 35 8378 8385 O
bleeding 36 44 8386 8394 O
from 45 49 8395 8399 O
cediranib 50 59 8400 8409 B-treatment
, 59 60 8409 8410 O
patients 61 69 8411 8419 O
who 70 73 8420 8423 O
are 74 77 8424 8427 O
on 78 80 8428 8430 O
greater 81 88 8431 8438 O
than 89 93 8439 8443 O
or 94 96 8444 8446 O
equal 97 102 8447 8452 O
to 103 105 8453 8455 O
2 106 107 8456 8457 B-lower_bound
anti 108 112 8458 8462 B-treatment
- 112 113 8462 8463 I-treatment
thrombotic 113 123 8463 8473 I-treatment
agents 124 130 8474 8480 I-treatment
, 130 131 8480 8481 O
including 132 141 8482 8491 O
but 142 145 8492 8495 O
not 146 149 8496 8499 O
limited 150 157 8500 8507 O
to 158 160 8508 8510 O
anti 161 165 8511 8515 B-treatment
- 165 166 8515 8516 I-treatment
platelet 166 174 8516 8524 I-treatment
agents 175 181 8525 8531 I-treatment
( 182 183 8532 8533 O
non 183 186 8533 8536 B-treatment
- 186 187 8536 8537 I-treatment
steroidal 187 196 8537 8546 I-treatment
anti 197 201 8547 8551 I-treatment
- 201 202 8551 8552 I-treatment
inflammatory 202 214 8552 8564 I-treatment
drugs 215 220 8565 8570 I-treatment
[ 221 222 8571 8572 O
NSAIDs]/aspirin 222 237 8572 8587 B-treatment
, 237 238 8587 8588 O
clopidogrel 239 250 8589 8600 B-treatment
) 250 251 8600 8601 O
, 251 252 8601 8602 O
heparin 253 260 8603 8610 B-treatment
, 260 261 8610 8611 O
low 262 265 8612 8615 B-treatment
molecular 266 275 8616 8625 I-treatment
weight 276 282 8626 8632 I-treatment
heparin 283 290 8633 8640 I-treatment
( 291 292 8641 8642 I-treatment
LMWH 292 296 8642 8646 I-treatment
) 296 297 8646 8647 I-treatment
, 297 298 8647 8648 O
warfarin 299 307 8649 8657 B-treatment
, 307 308 8657 8658 O
and 309 312 8659 8662 O
a 313 314 8663 8664 O
direct 315 321 8665 8671 B-treatment
thrombin 322 330 8672 8680 I-treatment
inhibitor 331 340 8681 8690 I-treatment
, 340 341 8690 8691 O
will 342 346 8692 8696 O
be 347 349 8697 8699 O
excluded 350 358 8700 8708 O

men 0 3 8709 8712 B-gender
treated 4 11 8713 8720 O
or 12 14 8721 8723 O
enrolled 15 23 8724 8732 O
on 24 26 8733 8735 O
this 27 31 8736 8740 O
protocol 32 40 8741 8749 O
must 41 45 8750 8754 O
also 46 50 8755 8759 O
agree 51 56 8760 8765 B-contraception_consent
to 57 59 8766 8768 I-contraception_consent
use 60 63 8769 8772 I-contraception_consent
adequate 64 72 8773 8781 I-contraception_consent
contraception 73 86 8782 8795 I-contraception_consent
prior 87 92 8796 8801 O
to 93 95 8802 8804 O
the 96 99 8805 8808 O
study 100 105 8809 8814 O
, 105 106 8814 8815 O
for 107 110 8816 8819 O
the 111 114 8820 8823 O
duration 115 123 8824 8832 O
of 124 126 8833 8835 O
study 127 132 8836 8841 O
participation 133 146 8842 8855 O
, 146 147 8855 8856 O
and 148 151 8857 8860 O
for 152 155 8861 8864 O
4 156 157 8865 8866 B-upper_bound
months 158 164 8867 8873 I-upper_bound
after 165 170 8874 8879 I-upper_bound
completion 171 181 8880 8890 O
of 182 184 8891 8893 O
cediranib 185 194 8894 8903 B-treatment
and 195 198 8904 8907 O
olaparib 199 207 8908 8916 B-treatment
administration 208 222 8917 8931 O

patients 0 8 8932 8940 O
who 9 12 8941 8944 O
are 13 16 8945 8948 O
on 17 19 8949 8951 O
3 20 21 8952 8953 O
antihypertensive 22 38 8954 8970 B-treatment
medications 39 50 8971 8982 I-treatment
are 51 54 8983 8986 O
highly 55 61 8987 8993 O
recommended 62 73 8994 9005 O
to 74 76 9006 9008 O
be 77 79 9009 9011 O
followed 80 88 9012 9020 O
by 89 91 9021 9023 O
a 92 93 9024 9025 O
cardiologist 94 106 9026 9038 O
or 107 109 9039 9041 O
blood 110 115 9042 9047 O
pressure 116 124 9048 9056 O
specialist 125 135 9057 9067 O
for 136 139 9068 9071 O
management 140 150 9072 9082 O
of 151 153 9083 9085 O
BP 154 156 9086 9088 O
while 157 162 9089 9094 O
on 163 165 9095 9097 O
protocol 166 174 9098 9106 O

patients 0 8 9107 9115 O
with 9 13 9116 9120 O
hypertension 14 26 9121 9133 B-chronic_disease
may 27 30 9134 9137 O
be 31 33 9138 9140 O
managed 34 41 9141 9148 O
with 42 46 9149 9153 O
up 47 49 9154 9156 O
to 50 52 9157 9159 O
a 53 54 9160 9161 O
maximum 55 62 9162 9169 O
of 63 65 9170 9172 O
3 66 67 9173 9174 B-upper_bound
antihypertensive 68 84 9175 9191 B-treatment
medications 85 96 9192 9203 I-treatment

patients 0 8 9204 9212 O
with 9 13 9213 9217 O
long 14 18 9218 9222 O
- 18 19 9222 9223 O
standing 19 27 9223 9231 O
stable 28 34 9232 9238 O
grade 35 40 9239 9244 O
2 41 42 9245 9246 O
neuropathy 43 53 9247 9257 O
or 54 56 9258 9260 O
prior 57 62 9261 9266 B-treatment
grade 63 68 9267 9272 I-treatment
2 69 70 9273 9274 I-treatment
treatment 71 80 9275 9284 I-treatment
- 80 81 9284 9285 O
related 81 88 9285 9292 O
hypothyroidism 89 103 9293 9307 B-chronic_disease
requiring 104 113 9308 9317 O
treatment 114 123 9318 9327 O
, 123 124 9327 9328 O
provided 125 133 9329 9337 O
free 134 138 9338 9342 O
T4 139 141 9343 9345 O
within 142 148 9346 9352 O
normal 149 155 9353 9359 O
range 156 161 9360 9365 O
, 161 162 9365 9366 O
may 163 166 9367 9370 O
be 167 169 9371 9373 O
considered 170 180 9374 9384 O
eligible 181 189 9385 9393 O
after 190 195 9394 9399 O
discussion 196 206 9400 9410 O
with 207 211 9411 9415 O
the 212 215 9416 9419 O
study 216 221 9420 9425 O
principal 222 231 9426 9435 O
investigator 232 244 9436 9448 O
( 245 246 9449 9450 O
PI 246 248 9450 9452 O
) 248 249 9452 9453 O

screening 0 9 9454 9463 O
brain 10 15 9464 9469 B-treatment
MRI 16 19 9470 9473 I-treatment
( 20 21 9474 9475 O
or 21 23 9475 9477 O
CT 24 26 9478 9480 B-treatment
if 27 29 9481 9483 O
MRI 30 33 9484 9487 O
contraindicated 34 49 9488 9503 O
) 49 50 9503 9504 O
will 51 55 9505 9509 O
be 56 58 9510 9512 O
required 59 67 9513 9521 O
for 68 71 9522 9525 O
patients 72 80 9526 9534 O
with 81 85 9535 9539 O
recurrent 86 95 9540 9549 O
NSCLC 96 101 9550 9555 B-cancer
, 101 102 9555 9556 O
TNBC 103 107 9557 9561 B-cancer
, 107 108 9561 9562 O
or 109 111 9563 9565 O
SCLC 112 116 9566 9570 O
; 116 117 9570 9571 O
brain 118 123 9572 9577 O
MRI 124 127 9578 9581 O
( 128 129 9582 9583 O
or 129 131 9583 9585 O
CT 132 134 9586 9588 O
if 135 137 9589 9591 O
MRI 138 141 9592 9595 O
contraindicated 142 157 9596 9611 O
) 157 158 9611 9612 O
is 159 161 9613 9615 O
required 162 170 9616 9624 O
for 171 174 9625 9628 O
PDAC 175 179 9629 9633 O
if 180 182 9634 9636 O
clinically 183 193 9637 9647 O
suspected 194 203 9648 9657 O
by 204 206 9658 9660 O
patient 207 214 9661 9668 O
's 214 216 9668 9670 O
symptoms 217 225 9671 9679 O
or 226 228 9680 9682 O
neurological 229 241 9683 9695 O
exam 242 246 9696 9700 O

subjects 0 8 9701 9709 O
with 9 13 9710 9714 O
treated 14 21 9715 9722 O
limited 22 29 9723 9730 O
stage 30 35 9731 9736 O
basal 36 41 9737 9742 B-cancer
cell 42 46 9743 9747 I-cancer
or 47 49 9748 9750 O
squamous 50 58 9751 9759 B-cancer
cell 59 63 9760 9764 I-cancer
carcinoma 64 73 9765 9774 I-cancer
of 74 76 9775 9777 I-cancer
the 77 80 9778 9781 I-cancer
skin 81 85 9782 9786 I-cancer
or 86 88 9787 9789 O
carcinoma 89 98 9790 9799 B-cancer
in 99 101 9800 9802 I-cancer
situ 102 106 9803 9807 I-cancer
of 107 109 9808 9810 I-cancer
the 110 113 9811 9814 I-cancer
breast 114 120 9815 9821 I-cancer
or 121 123 9822 9824 I-cancer
cervix 124 130 9825 9831 I-cancer
are 131 134 9832 9835 O
eligible 135 143 9836 9844 O

the 0 3 9845 9848 O
clinical 4 12 9849 9857 O
indication 13 23 9858 9868 O
for 24 27 9869 9872 O
therapeutic 28 39 9873 9884 B-treatment
anticoagulation 40 55 9885 9900 I-treatment
must 56 60 9901 9905 O
be 61 63 9906 9908 O
clearly 64 71 9909 9916 O
documented 72 82 9917 9927 O
prior 83 88 9928 9933 O
to 89 91 9934 9936 O
enrollment 92 102 9937 9947 O
and 103 106 9948 9951 O
must 107 111 9952 9956 O
be 112 114 9957 9959 O
discussed 115 124 9960 9969 O
with 125 129 9970 9974 O
the 130 133 9975 9978 O
P.I 134 137 9979 9982 O

therapeutic 0 11 9983 9994 B-treatment
anticoagulation 12 27 9995 10010 I-treatment
for 28 31 10011 10014 O
prior 32 37 10015 10020 O
thromboembolic 38 52 10021 10035 B-chronic_disease
events 53 59 10036 10042 I-chronic_disease
is 60 62 10043 10045 O
permitted 63 72 10046 10055 O

